Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis.
Objective
To characterize the etiologies and clinical features at diagnosis of patients with hemophagocytic lymphohistiocytosis (HLH) and correlate these baseline features with survival using an etiopathogenically guided multivariable model.


Patients and Methods
The Spanish Group of Autoimmune Diseases HLH Study Group, formed in 2013, is aimed at collecting adult patients with HLH diagnosed in internal medicine departments between January 3, 2013, and October 28, 2017.


Results
The cohort consisted of 151 patients (91 men; mean age, 51.4 years). After a mean follow-up of 17 months (range, 1-142 months), 80 patients died. Time-to-event analyses for death identified a worse survival curve for patients with neoplasia (P<.001), mixed microbiological infections (P=.02), and more than 1 infection (P=.01) and glucocorticoid monotherapy (P=.02). According to univariate analyses, platelets of less than 100,000/mm3 (hazard ratio [HR], 3.39; 95% CI, 1.37-8.40), leukopenia (HR, 1.81; 95% CI, 1.01-3.23), severe hyponatremia (HR, 1.61; 95% CI, 1.02-2.54), disseminated intravascular coagulation (HR, 1.87; 95% CI, 1.05-3.34), bacterial infection (HR, 1.99; 95% CI, 1.09-3.63), mixed microbiological infections (HR, 3.42; 95% CI, 1.38-8.46), and 2 or more infectious triggers (HR, 2.95; 95% CI, 1.43-6.08) were significantly associated with death. In contrast, peripheral adenopathies (HR, 0.63; 95% CI, 0.40-0.98) and the immunosuppressive drug/intravenous immunoglobulin/biological therapies (HR, 0.44; 95% CI, 0.20-0.96) were protective against all-cause mortality. Multivariable Cox proportional hazards regression analysis identified 2 or more infectious triggers (HR, 3.14; 95% CI, 1.28-7.68) as the only variable independently associated with death.


Conclusion
The mortality rate of adult patients diagnosed with HLH exceeds 50%. Infection with more than 1 microbiological agent was the only independent variable associated with mortality irrespective of the underlying disease, epidemiological profile, clinical presentation, and therapeutic management.
['Brito-Zerón|Pilar|P|', 'Kostov|Belchin|B|', 'Moral-Moral|Pedro|P|', 'Martínez-Zapico|Aleida|A|', 'Díaz-Pedroche|Carmen|C|', 'Fraile|Guadalupe|G|', 'Pérez-Guerrero|Patricia|P|', 'Fonseca|Eva|E|', 'Robles|Angel|A|', 'Vaquero-Herrero|María P|MP|', 'Calvo|María Andrés|MA|', 'Forner|María José|MJ|', 'Morcillo|Cesar|C|', 'Larrañaga|José|J|', 'Rodriguez-Carballeira|Monica|M|', 'Ruiz-Muñoz|Manuel|M|', 'Hurtado-García|Robert|R|', 'Prieto-González|Sergio|S|', 'Aguilar|Asun Aljibe|AA|', 'Caminal-Montero|Luis|L|', 'Hernández-Jiménez|Pilar|P|', 'Fernández-Viagas|Cristina Rodríguez|CR|', 'Castro|Pedro|P|', 'Massó|Victoria Morell|VM|', 'Flores-Chavez|Alejandra|A|', 'Ramos-Casals|Manuel|M|', '|||']
GC, glucocorticoid HLH, hemophagocytic lymphohistiocytosis ICU, intensive care unit ID, immunosuppressive drug IVIG, intravenous immunoglobulin NK, natural killer